End of the road: Confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma

Neuro-Oncology

Volumn 17, Issue 5, 2015, Pages 634-635

  Mason, Warren P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CILENGITIDE; ANTINEOPLASTIC AGENT; DNA LIGASE; DNA METHYLTRANSFERASE; SNAKE VENOM; TUMOR SUPPRESSOR PROTEIN;

CANCER CENTER; CANCER SURVIVAL; CANCER THERAPY; EDITORIAL; GLIOBLASTOMA; HUMAN; TREATMENT OUTCOME; BRAIN NEOPLASMS; FEMALE; GENETICS; MALE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; SNAKE VENOMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84928911049     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov018     Document Type: Editorial

References (13)

1. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
2. Bello L, Francolini M, Marthyn P, et al. a(v)B3 and a(v)B5 integrin expression in glioma periphery. Neurosurgery. 2001;49(2): 380-389.
3. Uhm JH, Dooley NP, Kyritsis AP, et al. Vitronectin, a glioma-derived extracellular matrix protein, protect tumor cells from apoptotic death. Clin Cancer Res. 1999;5(6):1587-1594.
4. Smith JW. Cilengitide Merck. Curr Opin Investig Drugs. 2003;4(6): 741-745.
5. Yamada S, Bu XY, Khankaldyyan V, et al. Effect of the angiogenesis inhibitor cilengitide (EMD121974) on glioblastoma growth in nude mice. Neurosurgery. 2006;59(6):1304-1312.
6. Lomonaco SL, Finnis S, Xiang C, et al. Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro Oncol. 2011;13(8): 857-865.
7. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated scheduledependency. Int J Cancer. 2009;124(11):2719-2727.
8. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012;118(22):5601-5607.
9. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651-1657.
10. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(16): 2712-2718.
11. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100-1108.
12. Nabors LB, Fink KL, Mikkelsen T, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17(5):708-717.
13. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26(34):5610-5617.